Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Genes encoding proteins that have key functions in the DNA damage response, such as p53 and its inhibitors MDM2 and MDMX, are most likely candidates to harbor allelic variants that influence breast cancer susceptibility.
|
30956778 |
2019 |
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Racial/ethnic differences in expression profiles of mtp53, MDM2, and MDM2-C and associations with breast cancer-specific and overall mortality.
|
30470976 |
2019 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therefore, the role of MDM2 and MDMX in the context of mtp53 in BCs requires further clarification.
|
31489110 |
2019 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
MDM2 drives TNBC circulating tumor cells (CTCs) in mice, but the context-dependent influences of MDM2 and MDMX on different subtypes of breast cancers expressing mtp53 have not been determined.
|
30642351 |
2019 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Altogether, these findings suggest that SCF<sup>FBXO22</sup> targets HDM2 for degradation and possesses inhibitory effects against breast cancer tumor cell invasion and metastasis.
|
31138683 |
2019 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
CHD1L promotes cell cycle progression and cell motility by up-regulating MDM2 in breast cancer.
|
30972184 |
2019 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
A Numb-Mdm2 fuzzy complex reveals an isoform-specific involvement of Numb in breast cancer.
|
29269425 |
2018 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, oncoprotein HBXIP suppresses miR-18b to elevate MDM2 and activates pAKT to phosphorylate MDM2 for enhancing the interaction between MDM2 and p53, leading to p53 degradation in promotion of breast cancer growth.
|
30181579 |
2018 |
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Significant Association of the MDM2 T309G Polymorphism with Breast Cancer Risk in a Turkish Population
|
29699057 |
2018 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Together, our finding revealed a novel modifier for p53/MDM2 complex and suggested SHARPIN as a promising target to restore p53 function in breast cancer.
|
28063307 |
2017 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
The role of MDM2 and MDM4 in breast cancer development and prevention.
|
28096293 |
2017 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
The Functional Roles of the MDM2 Splice Variants P2-MDM2-10 and MDM2-∆5 in Breast Cancer Cells.
|
28844019 |
2017 |
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Allele 399Gln (OR 1.57; 95% CI 1.05-2.35), Arg399Gln of gene XRCC1 heterozygous genotype (OR 2.77; 95% CI 1.60-4.80), the combination of Arg399Gln/Arg72Pro of genes XRCC1/TP53 heterozygous genotype (OR 3.98; 95% CI 1.57-10.09), Arg399Gln/T309G of genes XRCC1/MDM2 (OR 3.0; 95% CI 1.18-7.56), as well as Arg399Gln/Arg72Pro/T309G of genes XRCC1/TP53/MDM2 (OR 6.40; 95% CI 1.18-34.63) were associated with BC in Kyrgyz women.
|
29132330 |
2017 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Taken together these data indicate that in some ER+ breast cancers the estrogen-MDM2-Rb-E2F1 axis is a central hub for estrogen-mediated p53-independent signal transduction.
|
28615518 |
2017 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
We also propose several strategies for inhibiting the NFAT1-MDM2-p53 pathway, which could be useful for developing more specific and effective inhibitors for breast cancer therapy.
|
29096894 |
2017 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
LC-MS/MS-based targeted proteomics quantitatively detects the interaction between p53 and MDM2 in breast cancer.
|
27826076 |
2017 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Gossypol has anti-cancer effects by dual-targeting MDM2 and VEGF in human breast cancer.
|
28274247 |
2017 |
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate.
|
27081698 |
2016 |
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We report that the expression of MDM4 and MDM2 is elevated in primary human breast cancers of luminal A/B subtypes and associates with ERα-positive disease, independently of p53 mutation status.
|
26909605 |
2016 |
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In summary, we report for the first time that SQ shows excellent anti-breast cancer activity in vivo and in vitro and induces p53-independent apoptosis, which is associated with MDM2 inhibition.
|
27693458 |
2016 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3.
|
26883108 |
2016 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the role of MDM2 in epithelial-to-mesenchymal transition (EMT) and the underlying mechanisms in breast cancer cells in vitro and in vivo.
|
27184007 |
2016 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Platycodin D, a metabolite of Platycodin grandiflorum, inhibits highly metastatic MDA-MB-231 breast cancer growth in vitro and in vivo by targeting the MDM2 oncogene.
|
27432230 |
2016 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, G613 represents a potent small-molecule inhibitor of the Mdm2-p53 interaction and can serve as a promising lead for developing a new class of anti-cancer therapy for breast cancer patients.
|
26556313 |
2016 |
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
However, the results obtained from the combination of SNPs 344T>A of MDM2 and 72 Arg/Pro of p53, do not support the hypothesis of the prominent role of common p53 and MDM2 variations in the genetic mechanisms of chemotherapy resistance in breast cancer.
|
27569097 |
2016 |